This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: I70.0 (atherosclerosis of aorta) | Special Copayment Reduction: V192 (special copayment reduction for heart disease: 5% copayment for up to 30 days from the registration date) |
| B. Synonyms | Aortic atherosclerosis, Aortic sclerosis, abdominal aortic atherosclerosis, Aortic plaque, aortic calcification |
| C. Adult onset | Atherosclerotic plaque progresses from the 40s, and clinically significant aortic atherosclerosis appears in the 60s–70s. Early onset and rapid progression are seen in men and in patients with hypertension, smoking and hyperlipidemia. |
| 1. History | Foundations: von Haller's description of atheroma in 1755 and Marchand's naming of atherosclerosis (Arteriosklerose) in 1904. Milestones: the lipid hypothesis (Anitschkov, 1913) and the discovery of statins (1970s). |
| 2. Causes | Hypertension, hyperlipidemia (elevated LDL-C), smoking, diabetes, obesity, advanced age, chronic kidney disease and hyperhomocysteinemia are the main risk factors. |
| 3. Genetics | PCSK9, LDLR and APOE variants affect LDL metabolism and atherosclerosis risk. The 9p21.3 risk locus is the strongest cardiovascular risk locus identified by GWAS. |
| 4. General epidemiology | Aortic atherosclerosis is observed in 70–80% of adults aged 65 and older. Aortic plaque is a cause of aortic aneurysm, embolic stroke and peripheral arterial occlusive disease. |
| 5. Pathophysiology | Endothelial dysfunction → monocyte infiltration → foam cell formation (fatty streak) → fibrous plaque → vulnerable plaque → rupture and thrombosis. Oxidized LDL and inflammatory mediators are key. |
| 6. Symptoms | Mostly asymptomatic. With progression: visceral ischemia (mesenteric ischemia), intermittent claudication of the lower limbs, and hypertension due to renal artery stenosis. Stroke and blue toes due to plaque embolism may occur. |
| 7. Signs | Reduced aortic pulsation, absent lower-limb pulses, abdominal bruit, blue toes (trash foot). Aortic plaque (thickness, mobility) confirmed on transesophageal echocardiography. |
| 8. Screening | Abdominal ultrasound (aortic size, plaque), CT aortography, transesophageal echocardiography. The need for treatment is assessed by cardiovascular risk calculation (ASCVD Risk Score). |
| 9. Diagnosis | Abdominal and chest CT, MR angiography, transesophageal echocardiography and vascular ultrasound are used to evaluate plaque location, thickness, morphology, calcification and mobility. |
| 10. Treatment | Statins (high intensity, adding a PCSK9 inhibitor if possible), antiplatelet agents, control of hypertension and diabetes, smoking cessation. Endovascular intervention or surgery is considered for severe aortic stenosis or embolizing plaque. |
| 11. Prognosis | Aortic plaque is a strong marker of cardiovascular risk. Thick (≥4mm) or mobile plaques carry a 2–5 times higher risk of embolic stroke. Statin therapy can halt plaque progression and achieve partial regression. |
| 12. Prevention | Smoking cessation, strict control of hypertension, hyperlipidemia and diabetes, regular exercise, a Mediterranean diet and statin therapy are the cornerstones of primary prevention. |
| 13. References | Atherosclerotic plaque, cardiovascular risk, and lipid-lowering strategies: a narrative review (2025) … and 9 other papers |
The history of atherosclerosis goes back thousands of years. Atherosclerotic changes have been observed in the vessels of ancient Egyptian mummies (around 1550 BC), suggesting that atherosclerosis is not solely a problem of modern lifestyles. In the 18th century, Giovanni Battista Morgagni and Albrecht von Haller began to describe pathologically the fatty lesions of the arterial intima (atheroma), and the term "atheroma" derives from the Greek "athere," meaning gruel.
In the late 19th to early 20th century, Rudolf Virchow argued that atherosclerosis is not simply fat deposition but an inflammatory response of the vascular endothelium, a pioneering insight for the modern inflammatory theory of atherosclerosis. In 1904, Felix Marchand of Germany introduced the term "Arteriosklerose (arteriosclerosis)." In 1913, Nikolai Anitschkov of Russia succeeded in artificially inducing atherosclerosis by feeding rabbits a cholesterol diet, providing the first experimental proof that cholesterol (lipid) is a key cause of atherosclerosis. This was the origin of the modern lipid hypothesis.
In the 1950s–60s, the Framingham Heart Study and the Seven Countries Study established on a large epidemiological scale that serum cholesterol, blood pressure, smoking and other factors are independent risk factors for cardiovascular disease. In the 1970s, Akira Endo, the pioneer of statins, discovered HMG-CoA reductase inhibitors, and as lovastatin, simvastatin, pravastatin and others were introduced into clinical practice in the 1980s–90s, a revolutionary change occurred in cardiovascular risk reduction. In 1994, the 4S (Scandinavian Simvastatin Survival Study) first demonstrated that simvastatin reduces cardiovascular mortality by about 30% in patients after myocardial infarction. Since the 2000s, the development of PCSK9 inhibitors has made it possible to dramatically lower LDL-C that is difficult to lower sufficiently even with statins.
The causes of aortic atherosclerosis are the same as those of systemic atherosclerosis, with multiple risk factors acting in combination. Dyslipidemia, particularly elevated LDL cholesterol (LDL-C), is the most direct cause of atherosclerosis. Oxidized LDL deposits in the arterial intima and becomes the key starting point of atherosclerotic plaque formation. Hypertension places mechanical stress on the vascular endothelium, causing endothelial dysfunction, which becomes the starting point of atherosclerosis. In the aorta, fluctuations in shear stress due to turbulence are particularly large at vessel branch points (origin of the celiac artery, origin of the renal arteries, bifurcation of the common iliac arteries), so atherosclerotic plaque forms more rapidly at these sites.
Smoking promotes atherosclerosis through generation of reactive oxygen species, endothelial oxidative stress, platelet activation and reduced HDL-C. Diabetes (especially type 2) accelerates vascular endothelial dysfunction and atherosclerosis through advanced glycation end products (AGEs) from hyperglycemia, oxidative stress and insulin resistance. Obesity (especially abdominal obesity) increases the risk of atherosclerosis through insulin resistance, hypertriglyceridemia, low HDL and chronic inflammation (elevated CRP, IL-6). Advanced age itself raises the risk of atherosclerosis through endothelial cell senescence, increased inflammatory responses and changes in vascular structure. Chronic kidney disease is an independent cardiovascular risk factor that promotes atherosclerosis and vascular calcification through uremic toxins, inflammation and abnormal phosphate metabolism.